Cancer Immunology – News and Features

The tumor microenvironment is a harsh environment where metabolic adaptations are key. In this article, we explore how the metabolic constraints of the TME influence cancer and immune cells and dive into the metabolic cross-talk between them.

Traditionally, viruses have been thought of as a burden that cause disease. Now, viruses are being harnessed to tackle diseases that medicines can’t, helping fight cancer, genetic disorders and even infectious diseases.

Mapping a tumor's cellular neighborhood in three dimensions could identify potential targets for personalized cancer therapy.

“Cold” tumors are resistant to common immunotherapies. Stanford Medicine researchers have uncovered a master regulator that can be manipulated to prevent tumor growth in mice.

Tulane scientists found that an FDA-approved cancer drug may help the immune system clear out damaged cells that cause lung scarring, potentially restoring lung function in patients with pulmonary fibrosis.

A team of researchers from the University of Chicago, has identified a novel oncometabolite that accumulates in tumors and impairs immune cells’ ability to fight cancer.

A common pinworm medication may stop and reverse cancer growth in Merkel cell carcinoma, an aggressive form of skin cancer, according to research led by University of Arizona Cancer Center researchers.

New research demonstrates the role of the Galectin-1 protein in the nucleus of the cells surrounding the tumor-fibroblasts contributing to their activation.

In this article, Technology Networks spoke with Dr. Jack Hoppin and Dr. John Babich from Ratio Therapeutics to learn more about the recent radiopharmaceutical revolution.

A new study reveals how inherited genetic variants influence cancer biology. Analyzing data from over 1,000 patients across 10 cancer types, the study shows that these germline mutations affect protein activity.